STOCK TITAN
  1. Home
  2. News
  3. GSK

GSK plc American Depositary Shares (Each representing two Ordinary Shares) - GSK STOCK NEWS

Welcome to our dedicated page for GSK plc American Depositary Shares (Each representing two Ordinary Shares) news (Ticker: GSK), a resource for investors and traders seeking the latest updates and insights on GSK plc American Depositary Shares (Each representing two Ordinary Shares) stock.

GSK plc (formerly known as GlaxoSmithKline plc) is a leading British multinational pharmaceutical and biotechnology company headquartered in London, England. It ranks among the largest pharmaceutical companies globally by total sales, marking its influence in the industry. GSK’s core business segments include prescription medicines, vaccines, and consumer healthcare products. The company has a strong presence in therapeutic areas such as respiratory, oncology, antiviral treatments, and vaccines.

GSK leverages innovations in science and technology to develop and deliver a range of new treatments. Recent achievements include significant advancements in the development of respiratory therapies and cancer treatments. The company also focuses on combating infectious diseases through its strong vaccine portfolio, which includes vaccines for diseases like shingles, influenza, and hepatitis.

Financially, GSK demonstrates robust performance with consistent revenue growth driven by its diverse product pipeline and strategic market presence. The company engages in joint ventures to expand its reach, notably in the HIV market through its collaboration with ViiV Healthcare.

GSK’s commitment to improving global health is evidenced by its dynamic research and development efforts, strategic partnerships, and innovative product launches. Recent news highlights the company’s collaboration with Elegen and Elsie Biotechnologies, Inc., signifying its ongoing efforts to enhance its product offerings and research capabilities.

Investors and stakeholders can stay informed about GSK’s developments and performance by following the latest company news, financial updates, and product announcements.

News

Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer

Rhea-AI Summary
GSK announces positive results from the RUBY phase III trial for dostarlimab-gxly in combination with chemotherapy and niraparib for endometrial cancer. The trial shows significant improvements in overall survival and progression-free survival in the overall population and MMRp/MSS population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise

Rhea-AI Summary
GSK announces $2 million commitment in 2024 to boost adult immunization rates and health equity under COiMMUNITY Initiative. New resources and data show adult vaccination rates returning to pre-pandemic levels.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.25%
Tags
none
-
News

GSK Exercises Option to License Elsie Biotechnologies’ Discovery Platform to Find and Develop Novel Oligonucleotides

Rhea-AI Summary
Elsie Biotechnologies, Inc. announces GSK's licensing of their discovery platform after a successful research collaboration, potentially leading to development and commercial milestones. The agreement allows GSK to utilize Elsie's platform for oligonucleotide drug discovery, showcasing the platform's potential for next-generation RNA medicines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
none
News

GSK’s RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk

Rhea-AI Summary
GSK plc has announced that the US FDA has accepted an application to extend the indication of GSK’s adjuvanted respiratory syncytial virus (RSV) vaccine to adults aged 50-59 who are at increased risk for RSV disease. If approved, this would be the first vaccine available to help protect this population. The application is supported by positive results from a phase III trial evaluating the immune response and safety of the RSV vaccine in adults aged 50-59. The US FDA has set a Prescription Drug User Fee Act action date of June 7, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
none
-
News

Elegen and GSK Sign Collaboration and Licensing Agreement to Further Develop Elegen’s Cell-Free DNA Production Technology

Rhea-AI Summary
Elegen and GSK have entered into a multi-year collaboration and licensing agreement, allowing GSK to utilize Elegen's cell-free DNA manufacturing technology in the development of vaccines and medicines. The agreement includes upfront fees, purchase commitments of Elegen's ENFINIA DNA, near-term milestone payments, and a potential equity investment in Elegen by GSK, amounting to up to $35 million in near-term financial and development support and fees. Elegen's ENFINIA DNA, launched in March of last year, delivers NGS-verified, high-complexity, clonal-quality, linear DNA up to 7kb in as fast as seven business days. The technology is expected to save significant time and resources in the development of genetic medicines, potentially including mRNA, cell, and viral gene therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
none
-
News

GSK Enters Agreement to Acquire Aiolos Bio

Rhea-AI Summary
GSK plc (GSK) acquires Aiolos Bio, Inc. (Aiolos) for $1 billion upfront, expanding its respiratory pipeline with AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway. AIO-001 has the potential to redefine the standard-of-care with dosing every six months, reaching a broader portion of asthma patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
acquisition
News

GSK Awards $1M in COiMMUNITY Initiative Grants to Support Adult Immunization and Health Equity

Rhea-AI Summary
GSK plc (LSE/NYSE: GSK) announced the recipients of the inaugural grant program of the COiMMUNITY Initiative, a multipronged effort to support the design of a more systematic, collaborative, and equitable approach to increasing adult immunization rates in the US. Each grant-funded project is receiving between $50,000 and $175,000 out of a total $1 million in funding to address long-standing barriers to adult immunization in the US.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
none
-
News

GSK and Queer Eye’s Thom Filicia Partner on Blood Cancer Awareness Initiative

Rhea-AI Summary
GSK plc (LSE/NYSE: GSK) Launches Mapping Myelofibrosis Initiative in Partnership with Thom Filicia to Raise Awareness for Myelofibrosis (MF) - a Complex Blood Cancer Affecting 25,000 People in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
none
-
News

New Data for AREXVY, GSK’s RSV Vaccine, Show Potential to Help Protect Adults Aged 50 to 59 at Increased Risk for RSV Disease

Rhea-AI Summary
GSK announces positive preliminary results from phase III trial of AREXVY vaccine in adults aged 50 to 59 at increased risk for RSV disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
none
News

Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anemia

Rhea-AI Summary
GSK's Ojjaara (momelotinib) receives FDA approval for the treatment of myelofibrosis patients with anemia, addressing key manifestations of the disease. Myelofibrosis affects approximately 25,000 patients in the US. Limited treatment options have led to high discontinuation rates and poor prognosis for patients with anemia. Ojjaara is the only approved medicine for both newly diagnosed and previously treated myelofibrosis patients with anemia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
none

FAQ

What is the current stock price of GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)?

The current stock price of GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK) is $33.96 as of January 6, 2025.

What is the market cap of GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)?

The market cap of GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK) is approximately 68.9B.

What is GSK plc?

GSK plc is a British multinational pharmaceutical and biotechnology company headquartered in London, England, known for its prescription medicines, vaccines, and consumer healthcare products.

What are the main therapeutic areas GSK focuses on?

GSK focuses on respiratory diseases, oncology, antiviral treatments, and vaccines.

What recent collaborations has GSK engaged in?

Recent collaborations include partnerships with Elegen and Elsie Biotechnologies, Inc.

How does GSK expand its reach in the HIV market?

GSK expands its reach in the HIV market through its joint venture with ViiV Healthcare.

Where is the headquarters of GSK located?

GSK’s headquarters are located in London, England.

What achievements has GSK made recently?

GSK has made significant advancements in respiratory therapies, cancer treatments, and vaccine development.

What is the financial condition of GSK?

GSK demonstrates robust financial performance with consistent revenue growth driven by a diverse product pipeline and strategic market presence.

How can investors stay updated about GSK?

Investors can stay updated by following the latest company news, financial updates, and product announcements.

What does GSK's product portfolio include?

GSK's product portfolio includes prescription medicines, vaccines for various diseases, and consumer healthcare products.

Does GSK engage in research and development?

Yes, GSK is committed to improving global health through dynamic research and development efforts.
Stock GSK logo
GSK plc American Depositary Shares (Each representing two Ordinary Shares)

NYSE:GSK

GSK Rankings

#201 Ranked by Market Cap
#661 Ranked by Dividends

GSK Stock Data

68.94B
2.07B
0.06%
15.39%
0.9%
Drug Manufacturers - General
Healthcare
Link
United States of America
Brentford